P2Y12 Receptor
P2RY12geneP2Y12 is the platelet ADP receptor central to platelet aggregation and thrombosis; therapeutic target for antiplatelet therapy.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencehigh
RationaleADP-activated platelet receptor; antithrombotic target; clopidogrel and prasugrel antagonist.
Druggability
DruggableYes
Known drugs / candidates15
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000169313
Type I vs Type II discrimination
ScoresType-II-associated
R — rupture / Type-I—
C — confounder / Type-II67
A — assay feasibility52
E — evidence strength52
T1DI (composite)7
Specificity differential (R−C)-51.7
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
3hypovolemia / dehydrationn/a
4tachyarrhythmian/a
5hypoxemia / respiratory failuremag 2
6hypertensive emergencyn/a
7high-demand / peri-operative stressn/a
Coverage: 2/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 4 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood — gene is not a circulating analyte; measure protein product or genotype
Collection tube
K2-EDTA whole blood (lavender-top)
Method / principle
SNP genotyping / sequencing; or immunoassay of encoded protein
Reagent / substrate
Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein
Platform
qPCR / NGS / array
Turnaround · availability
Send-out · Genotyping widely available; protein assay variable
Human genetic evidence
0.620
Open Targets association (myocardial_infarction)
Literature evidence(7)
- The Na/K-ATPase α1 subunit fine-tunes platelet P2Y12 function and mediates sex dimorphism-associated thrombosis.Blood advances · 2026 · PMID 41118620 · doi
- Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study.Arteriosclerosis, thrombosis, and vascular biology · 2025 · PMID 40109258 · doi
- Abacavir causes leukocyte/platelet crosstalk by activating neutrophil P2X7 receptors thus releasing soluble lectin-like oxidized low-density lipoprotein receptor-1.British journal of pharmacology · 2023 · PMID 36541109 · doi
- Platelet RNA Biomarker of Ticagrelor-Responsive Genes Is Associated With Platelet Function and Cardiovascular Events.Arteriosclerosis, thrombosis, and vascular biology · 2023 · PMID 38059352 · doi
- Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target.Arteriosclerosis, thrombosis, and vascular biology · 2011 · PMID 21512161 · doi
- Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.Vascular medicine (London, England) · 2007 · PMID 17615799 · doi
- Platelet genomics and the risk of atherothrombosis.Journal of thrombosis and haemostasis : JTH · 2007 · PMID 17635726 · doi
Clinical trials(5)
- Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary SyndromeNCT01994941 · PHASE4 · COMPLETED · Clopidogrel, Ticagrelor
- Bleeding in Patients Undergoing Urgent CABG During Dual Antiplatelet Therapy Including the New P2Y12 Receptor Inhibitors Prasugrel and TicagrelorNCT02030548 · TERMINATED
- Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers In Non ST Elevated acUte Coronary Syndromes With Initial Invasive IndicationNCT02618837 · PHASE4 · UNKNOWN · Downstream strategy, Upstream strategy
- Adopting a Precision Medicine Paradigm in Puerto Rico: Leveraging Ancestral Diversity to Identify Predictors of Clopidogrel Response in Caribbean HispanicsNCT03419325 · EARLY_PHASE1 · COMPLETED · CYP2C19 test, P2RY12 assay
- Safety and Efficacy of CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection Versus Conventional Antiplatelet Therapy After Complex Percutaneous Coronary Intervention: The PRECISE-PCI Randomized Clinical TrialNCT06283888 · PHASE4 · RECRUITING · CYP2C19 Genotype Guided DAPT, Conventional DAPT